NRHA 340B Update 

Representatives Abigail Spanberger (D-VA) and David McKinley (R-WV) sent a letter to U.S. Department of Health and Human Services (HHS) Secretary Alex Azar urging relief for the 340B Drug Pricing Program. The letter, signed by 215 other Representatives, told Azar that the pharma information company Kalderos’ 340B pay software gives drug manufacturers “tremendous leverage” over 340B covered entities. Further, the letter asked Azar to make it clear that manufacturers should not implement a 340B rebate model without approval from Health Resources and Services Administration (HRSA). NRHA is continuing to monitor actions surrounding the 340B Drug Pricing Program and will keep members up to date.